Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review

Benjamin P. Geisler; Lara Zahabi; Adam Edward Lang; Naomi Eastwood; Elaine Tennant; Ljiljana Lukic; Elad Sharon; Hai Hua Chuang; Chang Berm Kang; Knakita Clayton-Johnson; Ahmed Aljaberi; Haining Yu; Chinh Bui; Tuan Le Mau; Wen Cheng Li; Debbie Teodorescu; Ludwig Christian Hinske; Dennis L. Sun; Farrin A. Manian; Adam G. Dunn

doi:10.1186/s13643-021-01693-7

Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review

Benjamin P. Geisler, Lara Zahabi, Adam Edward Lang, Naomi Eastwood, Elaine Tennant, Ljiljana Lukic, Elad Sharon, Hai Hua Chuang, Chang Berm Kang, Knakita Clayton-Johnson, Ahmed Aljaberi, Haining Yu, Chinh Bui, Tuan Le Mau, Wen Cheng Li, Debbie Teodorescu, Ludwig Christian Hinske, Dennis L. Sun, Farrin A. Manian, Adam G. Dunn

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

12 Downloads (Pure)

Abstract

Background: Coronavirus disease 2019 (COVID-19) has no confirmed specific treatments. However, there might be in vitro and early clinical data as well as evidence from severe acute respiratory syndrome and Middle Eastern respiratory syndrome that could inform clinicians and researchers. This systematic review aims to create priorities for future research of drugs repurposed for COVID-19. Methods: This systematic review will include in vitro, animal, and clinical studies evaluating the efficacy of a list of 34 specific compounds and 4 groups of drugs identified in a previous scoping review. Studies will be identified both from traditional literature databases and pre-print servers. Outcomes assessed will include time to clinical improvement, time to viral clearance, mortality, length of hospital stay, and proportions transferred to the intensive care unit and intubated, respectively. We will use the GRADE methodology to assess the quality of the evidence. Discussion: The challenge posed by COVID-19 requires not just a rapid review of drugs that can be repurposed but also a sustained effort to integrate new evidence into a living systematic review. Trial registration: PROSPERO 2020 CRD42020175648

Original language	English
Article number	143
Number of pages	5
Journal	Systematic Reviews
Volume	10
Issue number	1
DOIs	https://doi.org/10.1186/s13643-021-01693-7
Publication status	Published - May 2021
Externally published	Yes

Keywords

COVID-19
MERS-CoV
Middle East respiratory syndrome Coronavirus
Repurposed
Repurposing
SARS
SARS-CoV2
Severe acute respiratory syndrome

Access to Document

10.1186/s13643-021-01693-7Licence: CC BY

Published versionFinal published version, 500 KBLicence: CC BY

Cite this

Geisler, B. P., Zahabi, L., Lang, A. E., Eastwood, N., Tennant, E., Lukic, L., Sharon, E., Chuang, H. H., Kang, C. B., Clayton-Johnson, K., Aljaberi, A., Yu, H., Bui, C., Le Mau, T., Li, W. C., Teodorescu, D., Hinske, L. C., Sun, D. L., Manian, F. A., & Dunn, A. G. (2021). Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review. Systematic Reviews, 10(1), Article 143. https://doi.org/10.1186/s13643-021-01693-7

@article{2c38e8de71b2407f9e810328d767a2db,

title = "Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review",

abstract = "Background: Coronavirus disease 2019 (COVID-19) has no confirmed specific treatments. However, there might be in vitro and early clinical data as well as evidence from severe acute respiratory syndrome and Middle Eastern respiratory syndrome that could inform clinicians and researchers. This systematic review aims to create priorities for future research of drugs repurposed for COVID-19. Methods: This systematic review will include in vitro, animal, and clinical studies evaluating the efficacy of a list of 34 specific compounds and 4 groups of drugs identified in a previous scoping review. Studies will be identified both from traditional literature databases and pre-print servers. Outcomes assessed will include time to clinical improvement, time to viral clearance, mortality, length of hospital stay, and proportions transferred to the intensive care unit and intubated, respectively. We will use the GRADE methodology to assess the quality of the evidence. Discussion: The challenge posed by COVID-19 requires not just a rapid review of drugs that can be repurposed but also a sustained effort to integrate new evidence into a living systematic review. Trial registration: PROSPERO 2020 CRD42020175648",

keywords = "COVID-19, MERS-CoV, Middle East respiratory syndrome Coronavirus, Repurposed, Repurposing, SARS, SARS-CoV2, Severe acute respiratory syndrome",

author = "Geisler, {Benjamin P.} and Lara Zahabi and Lang, {Adam Edward} and Naomi Eastwood and Elaine Tennant and Ljiljana Lukic and Elad Sharon and Chuang, {Hai Hua} and Kang, {Chang Berm} and Knakita Clayton-Johnson and Ahmed Aljaberi and Haining Yu and Chinh Bui and {Le Mau}, Tuan and Li, {Wen Cheng} and Debbie Teodorescu and Hinske, {Ludwig Christian} and Sun, {Dennis L.} and Manian, {Farrin A.} and Dunn, {Adam G.}",

year = "2021",

month = may,

doi = "10.1186/s13643-021-01693-7",

language = "English",

volume = "10",

journal = "Systematic Reviews",

issn = "2046-4053",

publisher = "BioMed Central Ltd.",

number = "1",

}

Geisler, BP, Zahabi, L, Lang, AE, Eastwood, N, Tennant, E, Lukic, L, Sharon, E, Chuang, HH, Kang, CB, Clayton-Johnson, K, Aljaberi, A, Yu, H, Bui, C, Le Mau, T, Li, WC, Teodorescu, D, Hinske, LC, Sun, DL, Manian, FA & Dunn, AG 2021, 'Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review', Systematic Reviews, vol. 10, no. 1, 143. https://doi.org/10.1186/s13643-021-01693-7

TY - JOUR

T1 - Repurposing existing medications for coronavirus disease 2019

T2 - protocol for a rapid and living systematic review

AU - Geisler, Benjamin P.

AU - Zahabi, Lara

AU - Lang, Adam Edward

AU - Eastwood, Naomi

AU - Tennant, Elaine

AU - Lukic, Ljiljana

AU - Sharon, Elad

AU - Chuang, Hai Hua

AU - Kang, Chang Berm

AU - Clayton-Johnson, Knakita

AU - Aljaberi, Ahmed

AU - Yu, Haining

AU - Bui, Chinh

AU - Le Mau, Tuan

AU - Li, Wen Cheng

AU - Teodorescu, Debbie

AU - Hinske, Ludwig Christian

AU - Sun, Dennis L.

AU - Manian, Farrin A.

AU - Dunn, Adam G.

PY - 2021/5

Y1 - 2021/5

N2 - Background: Coronavirus disease 2019 (COVID-19) has no confirmed specific treatments. However, there might be in vitro and early clinical data as well as evidence from severe acute respiratory syndrome and Middle Eastern respiratory syndrome that could inform clinicians and researchers. This systematic review aims to create priorities for future research of drugs repurposed for COVID-19. Methods: This systematic review will include in vitro, animal, and clinical studies evaluating the efficacy of a list of 34 specific compounds and 4 groups of drugs identified in a previous scoping review. Studies will be identified both from traditional literature databases and pre-print servers. Outcomes assessed will include time to clinical improvement, time to viral clearance, mortality, length of hospital stay, and proportions transferred to the intensive care unit and intubated, respectively. We will use the GRADE methodology to assess the quality of the evidence. Discussion: The challenge posed by COVID-19 requires not just a rapid review of drugs that can be repurposed but also a sustained effort to integrate new evidence into a living systematic review. Trial registration: PROSPERO 2020 CRD42020175648

AB - Background: Coronavirus disease 2019 (COVID-19) has no confirmed specific treatments. However, there might be in vitro and early clinical data as well as evidence from severe acute respiratory syndrome and Middle Eastern respiratory syndrome that could inform clinicians and researchers. This systematic review aims to create priorities for future research of drugs repurposed for COVID-19. Methods: This systematic review will include in vitro, animal, and clinical studies evaluating the efficacy of a list of 34 specific compounds and 4 groups of drugs identified in a previous scoping review. Studies will be identified both from traditional literature databases and pre-print servers. Outcomes assessed will include time to clinical improvement, time to viral clearance, mortality, length of hospital stay, and proportions transferred to the intensive care unit and intubated, respectively. We will use the GRADE methodology to assess the quality of the evidence. Discussion: The challenge posed by COVID-19 requires not just a rapid review of drugs that can be repurposed but also a sustained effort to integrate new evidence into a living systematic review. Trial registration: PROSPERO 2020 CRD42020175648

KW - COVID-19

KW - MERS-CoV

KW - Middle East respiratory syndrome Coronavirus

KW - Repurposed

KW - Repurposing

KW - SARS

KW - SARS-CoV2

KW - Severe acute respiratory syndrome

UR - http://www.scopus.com/inward/record.url?scp=85105616126&partnerID=8YFLogxK

U2 - 10.1186/s13643-021-01693-7

DO - 10.1186/s13643-021-01693-7

M3 - Article

C2 - 33962652

AN - SCOPUS:85105616126

SN - 2046-4053

VL - 10

JO - Systematic Reviews

JF - Systematic Reviews

IS - 1

M1 - 143

ER -

Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this